Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. ONON
6. DCOY
7. MSFT
8. AZO
9. RCL
10. VKTX

Go back to Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
(NASDAQ: MDCX) Delayed: 0.16 --0 (-0%)
Previous Close $0.16    52 Week High $ 
Open $0.16    52 Week Low $ 
Day High $0.16    P/E N/A 
Day Low $0.16    EPS $ 
Volume 12,973